Novel C5a receptor antagonists regulate neutrophil functions in vitro and in vivo

Journal of Immunology

Volumn 160, Issue 11, 1998, Pages 5616-5621

  Pellas, Theodore C ^a   Boyar, William ^a   Van Oostrum, Jan ^b   Wasvary, James ^a   Fryer, Lynn R ^a   Pastor, Gary ^a   Sills, Matthew ^a   Braunwalder, Albert ^a   Yarwood, Donna R ^a   Kramer, Richard ^a   Kimble, Earl ^a   Hadala, Joseph ^a   Haston, William ^a   Moreira Ludewig, Rocio ^a   Uziel Fusi, Susan ^a   Peters, Paul ^a   Bill, Kurt ^b   Wennogle, Lawrence P ^a  

^a Novartis Research Institute   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CD11B ANTIGEN; CGS 27913; CGS 32359; COMPLEMENT COMPONENT C5A; COMPLEMENT COMPONENT C5A RECEPTOR ANTAGONIST; INTEGRIN; SUPEROXIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; INFLAMMATION; INTRAVENOUS DRUG ADMINISTRATION; NEUTROPENIA; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PURIFICATION; RABBIT; SKIN EDEMA;

ANIMALS; ANTIGENS, CD; CELL SEPARATION; COMPLEMENT C5A; DIMERIZATION; EDEMA; HUMANS; INJECTIONS, INTRADERMAL; INJECTIONS, INTRAVENOUS; NEUTROPENIA; NEUTROPHILS; PEPTIDE FRAGMENTS; RABBITS; RECEPTOR, ANAPHYLATOXIN C5A; RECEPTORS, COMPLEMENT; RECOMBINANT PROTEINS; SWINE; SWINE, MINIATURE;

EID: 15444353437     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Nilsson, U. R., R. J. Mandle, Jr., and J. A. McConnell-Mapes. 1975. Human C3 and C5: subunit structure and modifications by trypsin and C42-C423. J. Immunol. 114:815.
2. Cochrane, C. G., and H. J. Muller-Eberhard. 1968. The derivation of two distinct anaphylatoxin activities from the third and fifth components of human complement. J. Exp. Med. 127:371.
3. Bodammer, G., and W. Vogt. 1970. Effect of anaphylatoxin (AT) upon capillary permeability in guinea pig skin. Naunvn-Schmiedebergs Arch. Pharmacol. 266:255.
4. Goldslein, I. M., F. Feit, and G. Weissmann. 1975. Enhancement of nitroblue tetrazolium dye reduction by leukocytes exposed to a component of complement in the absence of phagocytosis. J. Immunol. 114:516.
5. Fernandez, H. N., P. M. Henson, A. Otani, and T. E. Hugli. 1978. Chemotactic response to human C3a and C5a anaphylatoxins. I. Evaluation of C3a and C5a leukotaxis in vitro and under stimulated in vivo conditions. J. Immunol. 120:109.
6. Jose, P. J., I. K. Moss, R. N. Maini, and T. J. Williams. 1990. Measurement of the chemotactic complement fragment C5a in rheumatoid synovial fluids by radioimmunoassay: role of C5a in the acute inflammatory phase. Ann. Rheum. Dis. 49:747.
7. Takematsu, H., and H. Tagami. 1993. Quantification of chemotactic peptides (C5a anaphylatoxin and IL-8) in psoriatic lesional skin. Arch. Dermatol. 129:74.
8. Langlois, P. F., M. S. Gawryl, J. Zeller, and T. Lint. 1989. Accentuated complement activation in patient plasma during the adult respiratory distress syndrome: a potential mechanism for pulmonary inflammation. Heart Lung 18:71.
9. Homeister, J. W., and B. R. Lucchesi. 1994. Complement activation and inhibition in myocardial ischemia and reperfusion injury. Annu. Rev. Pharmacol. Toxicol. 34:17.
10. Konteatis, Z. D., S. J. Siciliano, G. Van Riper, C. J. Molineaux, S. Pandya, P. Fischer, H. Rosen, R. A. Mumford, and M. S. Springer. 1994. Development of C5a receptor antagonists: differential loss of functional responses. J. Immunol. 153:4200.
11. Kaneko, Y., N. Okada, L. Baranyi, T. Azuma, and H. Okada. 1995. Antagonistic peptides against human anaphylatoxin C5a. Immunology 86:149.
12. Morgan, E., J. Ember, S. Sanderson, W. Scholz, R. Buchner, R. Ye, and T. Hugli. 1993 Anti-C5a receptor antibodies: characterization of neutralizing antibodies specific for a peptide, C5aR-(9-29), derived from the predicted amino-terminal sequence of the human C5a receptor. J. Immunol. 151:377.
13. Zuiderweg E. R., D. G. Nettesheim, K. W. Mollison, and G. W. Carter. 1989. Tertiary structure of human complement component C5a in solution from nuclear magnetic resonance data. Biochemistry 28:172.
14. Siciliano, S. J., T. E. Rollins, J. DeMartino, Z. Konteatis, L. Malkowitz, G. Van Riper, S. Bondy, H. Rosen, and M. S. Springer. 1994. Two-site binding of C5a by its receptor: an alternative binding paradigm for G protein-coupled receptors. Proc. Natl. Acad. Sci. USA 91:1214.
15. Mandecki, W., K. W. Mollison, T. J. Boiling, B. S. Powell, G. W. Carter, and J. L. Fox. 1985. Chemical synthesis of a gene encoding the human complement fragment C5a and its expression in Escherichia coli. Proc. Natl. Acad. Sci. USA 82:3543.
16. Toth, M. J., L. Huwyler, W. C. Boyar, A. F. Braunwalder, D. Yarwood, J. Hadala, W. O. Haston, M. A. Sills, B. Seligmann, and N. Galakatos. 1994. The pharmacophore of the human C5a anaphylatoxin. Protein Sci. 3:1159.
17. Sambrook, J., E. F. Fritsch, and T. Maniatis. 1989. Molecular Cloning: A Laboratory Manual. Cold Spring Harbor Laboratory Press, Plainview, NY.
18. 125I]C5a to human neutrophil, monocyte and U-937 cell membranes. Mol. Immunol. 29:1319.
19. Seligmann. B., K. Patel, W. O. Haston, and J. J. Rediske. 1987. Fluorometer based multi-parameter analysis of phagocytic cell activation. Agents Actions 21:375.
20. Chapman-Kirkland, E., J. Wasvary, and B. Seligmann. 1991. Superoxide anion production from human neutrophils measured with an improved kinetic and endpoint microassay. J. Immunol. Methods 142:95.
21. i) and the concentration of inhibitor which causes 50 per cent inhibition (150) of an enzymatic reaction. Biochem. Pharmacol. 22:3099.
22. Psychoyos, S., S. Uziel-Fusi, M. M. Morrissey, V. Ganu, and C. W. Smith. 1991. Thick filter neutrophil chemotaxis performed in the absence of albumin. J. Immunol. Methods 137:37.
23. Moreira-Ludewig, R., and C. T. Healy. 1992. A rapid microtiter plate method for the detection of lysozyme release from human neutrophils. J. Pharmacol. Toxicol. Methods 27:95.
24. Allen, R. 1986. Phagocytic leukocyte oxygenation activities and chemiluminescence: a kinetic approach to analysis. Methods Enzymol. 133:449.
25. Kishimoto, T. K., R. S. Larson, A. L. Corbi, M. L. Dustin, D. E. Staunton, and T. A. Springer. 1989. The leukocyte integrins. Adv. Immunol. 46:149.
26. Fearon, D. T., and L. A. Collins. 1983. Increased expression of C3b receptors on polymorphonuclear leukocytes induced by chemotactic factors and by purification procedures. J. Immunol. 130:370.
27. Hellewell, P., H. Yarwood, and T. Williams. 1989. Characteristics of oedema formation induced by N-formyl-methionyl-leucyl-phenylalanine in rabbit skin. Br. J. Pharmacol. 97:181.
28. Pellas, T. C., C. Colombo, L. R. Fryer, G. Pastor, W. Haston, A. Raychaudhuri, B. Kotyuk, P. D. Greenspan, C. Healy, and G. DiPasquale. 1993. LTB4-induced transient neutropenia in the rat: a model for evaluating efficacy and bioavailability of LTB4 receptor antagonists. J. Pharmacol. Toxicol. Methods 30:137.
29. Drapeau, G., S. Brochu, D. Godin, L. Levesque, F. Rioux, and F. Marceau. 1993. Synthetic C5a receptor agonists: pharmacology, metabolism and in vivo cardiovascular and hematologic effects. Biochem. Pharmacol. 45:1289.
30. Kawai M., D. Quincy, B. Lane, K. Mollison, J. Luly, and G. Carter. 1991. Identification and synthesis of a receptor binding site of human anaphylatoxin C5a. J. Med. Chem. 34:2068.
31. Kawai, M., D. Quincy, B. Lane, K. Mollison, Y. Or, J. Luly, and G. Carter, 1992. Structure-function studies in a series of carboxyl-terminal octapeptide analogues of anaphylatoxin C5a. J. Med. Chem. 35:220.
32. Or, Y., R. Clark, B. Lane, K. Mollison, G. Carter, and J. Luly. 1992. Improvements in the minimum binding sequence of C5a: examination of His-67. J. Med. Chem. 35:402.
33. Sanderson, S. D., L. Kirnarsky, S. A. Sherman, S. M. Vogen, O. Prakash, J. A. Ember, A. M. Finch, and S. M. Taylor. 1995. Decapeptide agonists of human C5a: the relationship between conformation and neutrophil response. J. Med. Chem. 38:3669.